Advanced Gastroesophageal Cancer
Publication Date: January 5, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
Treatment
...notherapy and Targeted Therapy for Advanced G...
...-line Therapy...
...ecommendation 1.1For HER2-negative patients w...
...commendation 1.2For HER2-negative patients with es...
...ion 1.3For patients with ESCC and PD-L1 CPS ≥10...
...endation 1.4For patients with ESCC, a...
...ndation 1.5For patients with HER2-positive gastr...
...d- or Third-line Therap...
...ndation 2.1For patients with advanced...
...n 2.2For HER2-positive patients with gastri...